Clinical trial · no report yet · Phase 3
ECHELON-3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
- NCT04404283 ↗
- Active not recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- 32 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 10 | |
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Brentuximab vedotin; Rituximab; Lenalidomide; Placebo
- Arms
- Experimental Arm · Experimental
- Control Arm · Active comparator
- Enrollment
- 239
- Primary outcomes
- Overall survival (OS)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Aug 20, 2020
- Primary completion
- Jan 23, 2026
- Results posted
- No
- Registry record
- NCT04404283 · updated Jul 22, 2026
Publications
linked from the registry- Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, Bouabdallah K, Forward N, Bijou F, MacDonald D, Portell CA, Ghesquieres H, Nowakowski G, Yasenchak CA, Patterson M, Ho L, Rustia E, Fanale M, Jie F, Kim JA. Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2025 Mar 20;43(9):1061-1072. doi: 10.1200/JCO-24-02242. Epub 2025 Jan 7. PubMed 39772655
- Ward JP, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, Fischer A, Griffith M, Griffith OL, Fehniger TA, Bartlett NL. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2022 Mar 31;139(13):1999-2010. doi: 10.1182/blood.2021011894. PubMed 34780623